This case highlights the clinical and molecular complexity of DS-ALL, particularly in the presence of multiple concurrent high-risk alterations (including JAK2, NRAS, and EP300 mutations, the P2RY8-CRLF2 fusion, and iAMP21). This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.